



Theranostic radiopharmaceuticals for imaging/treatment of cancer MEDICIS-Promed Work Package 3

Francesco Cicone¹, Alice D'Onofrio², Roberto Formento Cavaier³, Ioanna Prionisti⁴, Annie Ringvall Moberg⁵, Ilyes Zahi³ Lausanne University Hospital¹, IST^{2,}, AAA³, University of Geneva⁴, CERN⁵

Introduction


Work package 3 (WP£) is one of the three work packages within MEDICIS-Promed. It consists of 5 out of a total of 15 Early stage Researchers (ESRs) and one work package leader who are all working at various places in Europe.

WP3 – Leader + ESRs positions

WP leader: Ilyes Zahi ESR1. Annie Ringvall Moberg ESR6. Roberto Formento Cavaier ESR8. Alice D'Onofrio ESRCH2. Francesco Cicone ESRCH3. Ioanna Prionisti

Objectives of WP3

- Optimised and industrial performant production of new radioisotopes for theranostic using mass separation technology.
- Synthesis and design of bio-conjugated molecules for the specific DNA-targeting of tumor cells.
 Radioimmunotherapy and biodistribution studies on small animals as a proof of concept of the chosen radionuclides.



CNAC

KU LEUVEN

MedAus

PAUL SCHERRE

INSTITUT

ESRs and their projects

ESR1. Annie Ringvall Moberg



In order to further develop ion sources and target units at ISOLDE, CERN, a non-radioactive test laboratory, Off-line 2, is currently under construction. Off-line 2 will also allow for improvements of beam manipulation techniques using a Radio-Frequency Quadrupole Cooler and Buncher (RFQCB). My primary task will be to take part in the construction and commissioning of Off-line 2 along with the RFQCB and also to further develop and improve the RFQCB.

Figure of Off-line 2. 1. ISOLDE Front-end, 2. 90 degree mass separator magnet, 3. Beam diagnostics, 4. Ion optics (quadrupole triplets), 5. RFQCB. *Image: Stuart Warren*

A part of the RFQCB assembly at the ISOLDE Off-line 2 facility.

PRODUCTION OF

HIGH SPECIFIC

ACTIVITIES

INNOVATIVES


RADIONUCLIDES

ESR6. Roberto Formento Cavaier



The objective of this work is to study the production of innovative radionuclides such as Tb-149 using a commercial middle sized high-current cyclotron (GIP Arronax) while exploiting the technology of the mass separator developed within the MEDICIS-PROMED project at CERN.








Arronax IBA C70 cyclotron, Nantes

CERN-MEDICIS mass separator (light blue)

ESR8. Alice D'Onofrio



The final goal of this project is the synthesis and the biological evaluation of bifunctional compounds for theranostic applications. Those compounds, consisting of a central DOTA chelator that will stabilize the radioisotope, will be functionalized with a DNA-targeting moiety to increase the efficacy of Auger electrons and with a mAb fragment for the specific recognition of tumor cells. Furthermore, we intend to evaluate the influence of *in-vivo* click chemistry and of a bio-cleavable linker on the pharmacokinetic and biological behavior of such complexes.



Desired bi-functional Radio-immuno conjugates


ESRCH2. Francesco Cicone



As a Nuclear Medicine physician, I am the end-user of the novel radio-immunoconjugates synthesized within the frame of the MEDICIS-PROMED with the aim of imaging and treating cancer. In particular, I will perform preliminary in vitro and in vivo tests on mouse models of human sarcoma and neuroblastoma, hopefully driving a successful



¹⁵²Tb-CHX-A"-DTPA-ScFv78Fc anti TEM1



translation into patient clinic.


Micro PET/SPECT/CT

24 hour

ESRCH3. Ioanna Prionisti



The radioisotopes produced at the CERN-MEDICIS facility will be implanted in rodents to assess their efficacy for the treatment of glioblastoma. The project focuses on developing new instruments and delivery methods for brachytherapy and investigates the impact and efficiency of these methods at the cellular and organ levels. In particular, the project investigates how brachytherapy affects the brain's microvasculature and immune system.



60 hours





Horizon 2020 European Union funding Defor Posparch & Ippovation

This research project has been supported by a Marie Skłodowska-Curie innovative training network fellowship of the European commission's horizon 2020 program under contract number 642889 MEDICIS-PROMED.